Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Oct;30(4):511–517. doi: 10.1111/j.1365-2125.1990.tb03808.x

D-penicillamine and D-penicillamine-protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis.

D A Joyce 1, R O Day 1
PMCID: PMC1368240  PMID: 2291865

Abstract

1. The plasma pharmacokinetics of D-penicillamine (D-pen) and D-penicillamine-albumin disulphide (D-pen-alb) were examined over a dosage interval in six patients with rheumatoid arthritis. In two of these, 24 h synovial fluid profiles of D-pen and D-pen-alb were also obtained. 2. D-pen was undetectable in plasma at the beginning of the study. The peak concentration (5.4 +/- 1.2 microM) occurred at between 45 min and 2 h and the mean elimination half-life was 0.6 h. D-pen-alb, however, was present at a mean plasma concentration of 19.1 microM prior to dosage, peaked at 26.2 microM and was eliminated with a half-life of 40 h. 3. D-pen concentrations in synovial fluid rose more slowly and peaked lower than in plasma. D-pen-alb was present in synovial fluid of the patients at 50.1% and 83.6%, respectively, of the simultaneous plasma concentration prior to dosage. Concentrations varied during the study interval, corresponding to changes in plasma concentrations. 4. These results demonstrate that D-pen forms stable conjugates with protein in treated patients. The presence of D-pen-alb in relatively high concentrations throughout the dosage interval contrasts with the low concentrations and rapid elimination of D-pen. Both D-pen and D-pen-alb were also shown to be present at the putative site of drug action (the inflamed synovial joint) in concentrations lower than those in plasma.

Full text

PDF
512

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Bergstrom R. F., Kay D. R., Harkcom T. M., Wagner J. G. Penicillamine kinetics in normal subjects. Clin Pharmacol Ther. 1981 Sep;30(3):404–413. doi: 10.1038/clpt.1981.180. [DOI] [PubMed] [Google Scholar]
  3. Bergstrom R. F., Kay D. R., Wagner J. G. The in vitro loss of penicillamine in plasma, albumin solutions, and whole blood: implications for pharmacokinetic studies of penicillamine. Life Sci. 1980 Jul 21;27(3):189–198. doi: 10.1016/0024-3205(80)90137-x. [DOI] [PubMed] [Google Scholar]
  4. Binderup L., Arrigoni-Martelli E. [14C]-D-Penicillamine: uptake and distribution in rat lymphocytes and macrophages. Biochem Pharmacol. 1979;28(2):189–192. doi: 10.1016/0006-2952(79)90501-x. [DOI] [PubMed] [Google Scholar]
  5. Bourke C. E., Miners J. O., Birkett D. J. Reversible metabolism of D-penicillamine in the rat. Drug Metab Dispos. 1984 Nov-Dec;12(6):798–799. [PubMed] [Google Scholar]
  6. Brooks P. M., Miners J. O., Smith K., Smith M. D., Fearnley I., Birkett D. J. Dose, plasma concentration and response relationships of D-penicillamine in patients with rheumatoid arthritis. J Rheumatol. 1984 Dec;11(6):772–775. [PubMed] [Google Scholar]
  7. Brown D. L., Cooper A. G., Bluestone R. Exchange of IgM and albumin between plasma and synovial fluid in rheumatoid arthritis. Ann Rheum Dis. 1969 Nov;28(6):644–651. doi: 10.1136/ard.28.6.644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dagher F. J., Lyons J. H., Finlayson D. C., Shamsai J., Moore F. D. Blood volume measurement: a critical study prediction of normal values: controlled measurement of sequential changes: choice of a bedside method. Adv Surg. 1965;1:69–109. [PubMed] [Google Scholar]
  9. Drummer O. H., Christophidis N., Horowitz J. D., Louis W. J. Measurement of penicillamine and N-acetylcysteine in human blood by high-performance liquid chromatography and electrochemical detection. J Chromatogr. 1986 Jan 24;374(2):251–257. doi: 10.1016/s0378-4347(00)83280-6. [DOI] [PubMed] [Google Scholar]
  10. Gaucher A., Netter P., Faure G., Schoeller J. P., Gerardin A. Diffusion of oxyphenbutazone into synovial fluid, synovial tissue, joint cartilage and cerebrospinal fluid. Eur J Clin Pharmacol. 1983;25(1):107–112. doi: 10.1007/BF00544025. [DOI] [PubMed] [Google Scholar]
  11. Gibbs K., Walshe J. M. Studies with 35S-labelled DL-penicillamine in patients with Wilson's disease. Q J Med. 1971 Apr;40(158):275–287. doi: 10.1093/oxfordjournals.qjmed.a067270. [DOI] [PubMed] [Google Scholar]
  12. Hurst N. P., Bell A. L., Nuki G. Studies of the effect of D-penicillamine and sodium aurothiomalate therapy on superoxide anion production by monocytes from patients with rheumatoid arthritis: evidence for in vivo stimulation of monocytes. Ann Rheum Dis. 1986 Jan;45(1):37–43. doi: 10.1136/ard.45.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jalava S., Saarimaa H., Anttila M., Sundquist H. Naproxen concentrations in serum, synovial fluid, and synovium. Scand J Rheumatol. 1977;6(3):155–157. doi: 10.3109/03009747709095441. [DOI] [PubMed] [Google Scholar]
  14. Joyce D. A., Wade D. N. Assay for D-penicillamine-protein conjugate in human plasma utilising chemical reduction followed by high-performance liquid chromatography with gold/mercury electrochemical detection. J Chromatogr. 1988 Sep 9;430(2):319–327. doi: 10.1016/s0378-4347(00)83167-9. [DOI] [PubMed] [Google Scholar]
  15. Joyce D. A., Wade D. N., Swanson B. R. The pharmacokinetics of albumin conjugates of D-penicillamine in rats. Drug Metab Dispos. 1989 Mar-Apr;17(2):208–211. [PubMed] [Google Scholar]
  16. Kukovetz W. R., Beubler E., Kreuzig F., Moritz A. J., Nirnberger G., Werner-Breitenecker L. Bioavailability and pharmacokinetics of D-penicillamine. J Rheumatol. 1983 Feb;10(1):90–94. [PubMed] [Google Scholar]
  17. Kyogoku K., Inoue K., Otake T., Noda K., Ohzeki M. [Determination of D-penicillamine and its metabolites in blood and urine]. Yakugaku Zasshi. 1982 Apr;102(4):322–327. doi: 10.1248/yakushi1947.102.4_322. [DOI] [PubMed] [Google Scholar]
  18. Lipsky P. E. Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes. J Clin Invest. 1984 Jan;73(1):53–65. doi: 10.1172/JCI111207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lodemann E. Transport of D- and L-penicillamine by mammalian cells. Biochem Biophys Res Commun. 1981 Sep 30;102(2):775–783. doi: 10.1016/s0006-291x(81)80199-4. [DOI] [PubMed] [Google Scholar]
  20. McKeown M. J., Hall N. D., Corvalan J. R. Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin Exp Immunol. 1984 Jun;56(3):607–613. [PMC free article] [PubMed] [Google Scholar]
  21. Patzschke K., Wegner L. A. Pharmakokinetische Untersuchungen nach Applikation von 14C-D-Penicillamin an Ratten. Arzneimittelforschung. 1977;27(6):1152–1158. [PubMed] [Google Scholar]
  22. Perrett D. The metabolism and pharmacology of D-penicillamine in man. J Rheumatol Suppl. 1981 Jan-Feb;7:41–50. [PubMed] [Google Scholar]
  23. Simkin P. A., Pizzorno J. E. Transynovial exchange of small molecules in normal human subjects. J Appl Physiol. 1974 May;36(5):581–587. doi: 10.1152/jappl.1974.36.5.581. [DOI] [PubMed] [Google Scholar]
  24. Soren A. Dissociation of acetylsalicylic acid in blood and joint fluid. Scand J Rheumatol. 1977;6(1):17–22. [PubMed] [Google Scholar]
  25. Staite N. D., Zoschke D. C., Messner R. P. Scavenging of hydrogen peroxide--a new mechanism of action for D-penicillamine in rheumatoid arthritis? N Engl J Med. 1984 Aug 23;311(8):538–539. doi: 10.1056/nejm198408233110817. [DOI] [PubMed] [Google Scholar]
  26. Wass M., Evered D. F. Transport of penicillamine across mucosa of the rat small intestine in vitro. Biochem Pharmacol. 1970 Apr;19(4):1287–1295. [PubMed] [Google Scholar]
  27. Watanabe H., Grimsley G., Major G. A., Dawkins R. L. Increased binding of D-penicillamine to monocytes in rheumatoid arthritis. Clin Immunol Immunopathol. 1986 Apr;39(1):173–178. doi: 10.1016/0090-1229(86)90217-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES